An experimental drug insert designed to reduce how often people with wet age-related macular degeneration need eye injections failed to meet its main goal in the first of two pivotal trials, its manufacturer announced.
EyePoint reported that DURAVYU, a vorolanib intravitreal insert, did not achieve the primary endpoint of the phase 3 LUGANO trial. That endpoint was changed from baseline in best corrected visual acuity, averaged across weeks 52 and 56, measured against on-label aflibercept, the current standard of care.
One correction to how this has been described elsewhere. The primary endpoint measured vision, not dosing frequency. Reduced treatment burden was a secondary endpoint, and it is the one the trial hit.
The Nine Patients at the Center of the Result
The company attributes the miss to an imbalance in the data rather than a failure of the drug, and the specifics are worth examining rather than accepting at face value.
Nine of 211 patients in the DURAVYU arm, about 4%, experienced vision loss of 15 letters or more due to causes unrelated to wet AMD. No patients in the aflibercept control arm experienced comparable unrelated vision loss. In an ad hoc analysis excluding that group, DURAVYU was non-inferior to aflibercept with a nominal p-value of 0.0096, according to the company's announcement. EyePoint also pointed to what it called an overperformance of the aflibercept control arm as a second confounder.
Two words in that explanation carry weight. "Ad hoc" means the analysis was not pre-specified before the data were unblinded, which is precisely the circumstance in which excluding inconvenient patients can produce a favorable result by chance or by choice. "Nominal" means the p-value was not adjusted for multiple comparisons and cannot be treated as confirmatory. Non-inferiority was reached only in that excluded-patient analysis, leaving the headline efficacy question to the second trial.
That does not make the explanation wrong. An asymmetric cluster of unrelated vision loss is a recognized way for a trial to be confounded, and regulators do consider such arguments. It does mean the argument is unproven, and the company itself has framed the second trial as the test. In an investor presentation, EyePoint disclosed that the mean change in vision from baseline was greater than five letters for aflibercept versus between zero and five letters for DURAVYU.
The Secondary Results and the Problem They Address
The endpoints DURAVYU did meet speak to a genuine difficulty in retinal care.
Standard treatment for wet AMD requires repeated injections into the eye, dosed on average every two months in the United States under a treat-and-extend protocol, indefinitely. That schedule is demanding for older patients, many of whom need someone to drive them, and real-world adherence often falls short of trial protocols. Vision loss from missed appointments is a documented problem.
LUGANO reported a 42 percent reduction in treatment burden compared with on-label aflibercept, achieving superiority with a nominal p-value <0.0001, translating to about two fewer injections on average through week 56. Among DURAVYU patients, 76 percent were free of supplemental injections through week 32 and 54 percent through week 56, with 79 percent receiving no more than one supplement through week 56. Anatomic control was comparable, with a four-micron difference in central subfield thickness at week 56.
Safety was reported as clean. There were no differences from the control group in cataracts, elevated intraocular pressure, or intraocular inflammation, and no cases of retinal vasculitis or severe intraocular inflammation. Company president and CEO Jay Duker said the drug appeared "safe in the LUGANO trial, as well as effective" at controlling leakage and reducing treatment burden, he told Healio.
Those safety findings carry real weight in this field, where sustained-release approaches in the eye have previously been associated with inflammation and device-related complications. A clean profile across repeat dosing is not a trivial result even in a trial that missed its main goal.
The insert is delivered via standard intravitreal injection and releases the drug for about six months, distinguishing it from repeatedly injected anti-VEGF biologics and surgically implanted delivery systems.
The Practical Position for Patients in Treatment Now
Nothing changes for anyone currently in treatment. DURAVYU is investigational and unavailable outside trials. Aflibercept and other anti-VEGF therapies remain the standard, and their evidence base is unaffected by this readout.
The people with a stake in the outcome are those managing the logistics of frequent injections, particularly patients who depend on family members for transportation and those in rural areas where a retina specialist may be hours away. A durable option would matter most to them, and this result delays rather than forecloses that possibility.
Anyone considering enrolling in a retinal trial should ask what the primary endpoint measures, since a trial can produce encouraging secondary data and still fail. Patients should also continue attending scheduled injection appointments, because interval extension decisions in wet AMD are made by a retina specialist based on imaging and vision, not by patient preference.
Sudden vision changes between appointments warrant a call to the retina practice rather than waiting for the next scheduled visit. New distortion in straight lines, a fresh blind spot, or a rapid drop in central vision can indicate that fluid has returned, and the interval between injections is precisely when that happens. Home monitoring with an Amsler grid is a routine instruction in this condition and is worth asking about if it has not been raised.
The competitive picture continues to move, with Ocular Therapeutix advancing a rival tyrosine kinase inhibitor implant for the same condition. Investors read EyePoint's results harshly, with shares falling by roughly two-thirds in a day, though analysts' reactions to the underlying data were mixed. A share price is not a clinical verdict, and readers should not treat one as evidence about whether a drug works. Mizuho called the miss a genuine overhang that cannot be dismissed until the second trial reports, while describing the secondary results as reinforcing the product's durability and safety.
What remains unknown is whether the second identical trial, LUCIA, which enrolled 475 patients, will meet its primary endpoint when topline data arrive in the fourth quarter, and whether the FDA would accept an ad hoc analysis as supportive evidence. EyePoint plans to file a new drug application in the first half of next year if the results support it and will present additional details at a retina meeting in late September.
Key Questions Answered
What was the trial testing? Whether DURAVYU, a drug insert released over about six months, preserved vision as well as standard aflibercept injections in wet age-related macular degeneration.
What did it miss? The primary endpoint is the change from baseline in best-corrected visual acuity, averaged across weeks 52 and 56, in the full dataset.
Why does the company say it missed? Because nine of 211 patients in the treatment arm lost 15 letters or more of vision from causes unrelated to wet AMD, with no comparable cases in the control arm, and because the control arm outperformed expectations.
Is that explanation confirmed? No. The supporting analysis was ad hoc rather than pre-specified, and its p-value was nominal rather than adjusted. A second trial is expected to settle the question.
What did the trial achieve? A 42 percent reduction in treatment burden versus aflibercept, roughly two fewer injections through week 56, and a safety profile with no differences from control in cataracts, eye pressure, or inflammation.
Can patients get this drug? No. It is investigational and available only in clinical trials.
Should anyone change their current treatment? No. Anti-VEGF injections remain the standard, and injection intervals are set by a retina specialist based on imaging and vision.
